CLEVELAND, OH – November 24, 2015
Orca Pharmaceuticals has entered into a transaction with Brickell Biotech, a clinical-stage pharmaceutical company focused on the development of dermalotology therapeutics, in which Brickell will assume the responsibility for the continued development of these RORy inhibitors.
â€œWe are excited about this new agreement with Orca Pharmaceuticals and look forward to having the opportunity to develop a topically applied, potent and selective small-molecule therapeutic for psoriasis, said Patricia Walker, M.D., Ph.D., President and Chief Scientific Officer of Brickell Biotech.
Dr Michael Hunter, CEO of Orca Pharmaceuticals commented, “We are delighted to partner this program with Brickell Biotech. Brickell’s deep knowledge of dermatological development will be invaluable in bringing these much needed treatments to patients”.